Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
6 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Purple Biotech Ltd.’s names, not what it holds today.
Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and none in 2023
Applications published
15
1 of them in 2025
Names they are printed under
4
a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
FAMEWAVE LTD. a subsidiary
IL, as the owner printed on each patent
4 publishedTYRNOVO LTD. a subsidiary
IL, as the owner printed on each patent. 1 more under the same name are not counted (printed in NI)
4 publishedIMMUNORIZON LTD. a subsidiary
IL, as the owner printed on each patent
5 publishedTYRNOVO LTD. a subsidiary
named as the applicant on its applications, in IL
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jan 21, 2025 | 12,201,592 | Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer | Pharmaceuticals | TYRNOVO LTD. |
| Feb 6, 2024 | 11,891,453 | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM) | Pharmaceuticals | FAMEWAVE LTD. |
| Jan 9, 2024 | 11,866,509 | Humanized antibodies against CEACAM1 | Pharmaceuticals | FAMEWAVE LTD. |
| Aug 30, 2022 | 11,427,647 | Polynucleotides encoding humanized antibodies against CEACAM1 | Pharmaceuticals | FAMEWAVE LTD. |
| Feb 9, 2021 | 10,912,745 | Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer | Pharmaceuticals | TYRNOVO LTD. |
| Feb 4, 2020 | 10,550,196 | Humanized antibodies against CEACAM1 | Pharmaceuticals | FAMEWAVE LTD. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 1, 2025 | 2025/0134837 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | Pharmaceuticals | TYRNOVO LTD. |
| Dec 26, 2024 | 2024/0425452 | ISOLATED TRANS ISOMER OF 3-(2-BROMO-3,4-DIHYDROXY-PHENYL)-N-(3,4,5-TRIHYDROXY-BENZYL)-THIOACRYLAMIDE | Pharmaceuticals | TYRNOVO LTD. |
| Dec 5, 2024 | 2024/0400679 | ANTI-ROR1 ANTIBODIES AND USES THEREOF | Pharmaceuticals | IMMUNORIZON LTD. |
| Jul 11, 2024 | 2024/0228658 | ANTI-5T4 ANTIBODIES AND USES THEREOF | Biotechnology | IMMUNORIZON LTD. |
| Jul 11, 2024 | 2024/0228626 | ANTI-NKG2D ANTIBODIES AND USES THEREOF | Biotechnology | IMMUNORIZON LTD. |
| Mar 21, 2024 | 2024/0092934 | ASSESSMENT OF CEACAM1 EXPRESSION ON TUMOR INFILTRATING LYMPHOCYTES | Pharmaceuticals | FAMEWAVE LTD. |
| Feb 29, 2024 | 2024/0067604 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI PD-1/PD-L1 ANTIBODIES FOR TREATING CANCER | Pharmaceuticals | TYRNOVO LTD. |
| Oct 5, 2023 | 2023/0312753 | PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOF | Biotechnology | IMMUNORIZON LTD. |
| Jun 23, 2022 | 2022/0195041 | PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOF | Biotechnology | IMMUNORIZON LTD. |
| Jul 22, 2021 | 2021/0220297 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | Pharmaceuticals | TYRNOVO LTD. · patent 12,201,592 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Biotechnology 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.